The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.
Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.
Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.
A 27-year-old experienced significant hair regrowth after a hair transplant with 4349 grafts, supported by minoxidil and finasteride, improving his confidence. He plans to update on further progress at 9–12 months.
Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.
The user is considering getting blood work to investigate the cause of ongoing hair loss despite using finasteride and dutasteride. Others suggest that while blood tests can provide useful health information, they may not change the hair treatment outcome.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.
The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.
A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.
Hair loss treatments like finasteride, minoxidil, and dutasteride are discussed, with users sharing mixed experiences about effectiveness and side effects. Some users report positive results, while others express concerns about side effects, highlighting the importance of personal choice.
A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.
A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
A long-term finasteride user is considering switching to dutasteride due to hair loss progression. Users share experiences with switching, noting side effects and varying effectiveness, with some experiencing shedding and others maintaining their hairline.
A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.
The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.